It is very uncertain whether ACUTE: Serelaxin changes hyperkalaemia compared with placebo (very low certainty).
The review found no eligible studies for this question.
Citrate probably leads to lower major bleeding compared with unfractionated heparin (moderate certainty).
It is very uncertain whether unfractionated heparin changes successful prevention of clotting compared with low molecular weight heparin (very low certainty).
Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether unfractionated heparin changes thrombocytopenia compared with low molecular weight heparin (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether unfractionated heparin changes major bleeding compared with no pharmacological anticoagulation (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Citrate showed no clear difference in death at 28 days compared with unfractionated heparin (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Citrate probably leads to higher successful prevention of clotting compared with unfractionated heparin (moderate certainty).
Citrate showed no clear difference in treatment cessation due to adverse events compared with unfractionated heparin (low certainty).
Citrate showed no clear difference in recovery of kidney function compared with unfractionated heparin (low certainty).
Citrate showed no clear difference in thrombocytopenia compared with unfractionated heparin (low certainty).